Health Technology Assessment (HTA) refers to the systematic evaluation of medical technologies—particularly medicinal products, medical devices, diagnostics, or care programmes—with regard to their benefits, risks, costs, and organisational impact. The aim is to support evidence-based decisions on reimbursement, pricing, and healthcare provision. In Germany, HTA plays a central role primarily in the context of early benefit assessment under AMNOG and within the Federal Joint Committee (G-BA).
Objectives and typical HTA questions
HTA does not only ask “Does it work?”, but “For whom does it work—and is it meaningfully affordable within the healthcare system?”. In addition to clinical efficacy and safety, it considers patient-relevant endpoints, real-world care, and economic aspects. The focus is often on the added benefit versus an appropriate comparator therapy and on whether the evidence is transferable to German healthcare practice.
- Clinical benefit: patient-relevant endpoints such as mortality, morbidity, quality of life
- Safety: adverse event profile and risks in different populations
- Economics: cost-effectiveness models, budget impact, sensitivity analyses
- Organisation/ethics: implementation, access, equal treatment, care pathways
Ultimately, an HTA does not provide an “absolute truth”, but a structured basis for decision-making. Depending on the data situation, benefits and uncertainties may be weighted differently, particularly when study designs or endpoints do not optimally fit the care context.
Methodology: evidence, comparator therapy, and endpoints
A robust HTA requires a clearly defined research question (PICO): population, intervention, comparator, and outcomes. Randomised trials are often the preferred source of evidence, but observational data can also be relevant, particularly for long-term effects, rare safety aspects, or healthcare delivery questions. Comparability is crucial: if the comparator therapy does not reflect routine care, the assessment can be challenging despite positive study results.
Typical methodological challenges include indirect comparisons, heterogeneous study populations, differing endpoint definitions, and missing quality-of-life data. PROs (patient-reported outcomes) must be collected using validated instruments to be accepted for benefit assessments. Subgroup analyses should be pre-specified and transparently justified to avoid misleading conclusions and to increase the robustness of the results.
In many HTA settings, it is also relevant whether surrogate endpoints (e.g., biomarker-based response) are recognised as sufficiently patient-relevant. If not, a programme may come under pressure in the HTA context despite regulatory acceptance, because transferability to hard clinical endpoints or quality of life is considered uncertain.
HTA in Germany and the EU: roles of the G-BA, IQWiG, and European procedures
In Germany, the Institute for Quality and Efficiency in Health Care (IQWiG), on behalf of the G-BA, assesses the added benefit of new medicinal products. The results feed into subsequent price negotiations and reimbursement conditions. For medical devices, the HTA pathway varies depending on product class and setting—for example, in hospitals via NUB procedures or via benefit assessments for new examination and treatment methods.
In parallel, Europe is moving towards a more harmonised approach for joint clinical assessments to reduce duplication and standardise the evidence base. For companies, this means that dossier content and evidence presentation increasingly need to be internationally compatible, without losing sight of national specifics (e.g., comparator therapy in Germany).
A practical consequence: study programmes should be documented early in a way that makes endpoints, populations, and analyses transparently traceable. HTA bodies review not only results, but also the internal consistency of the protocol, statistical analysis plan, data quality, and reporting.
Relevance for clinical trials
Does HTA mean the same as marketing authorisation?
Operationally, an HTA focus leads to high requirements for data quality, protocol adherence, and traceability of analyses. This also applies to resource use (e.g., hospitalizations, concomitant therapies), which can later feed into health economic models. For economic evaluations, assumptions, data sources, and sensitivity analyses must also be documented transparently so that the results remain traceable.
In addition, “HTA-ready” processes in study operations are important: clear definitions for protocol deviations, consistent collection of concomitant therapies, and a robust data management strategy. For example, if subgroup decisions are based on biomarkers, the diagnostic quality (sample logistics, laboratory methods, cut-offs) must be documented in such a way that the results remain interpretable in an HTA context.
Frequently Asked Questions (FAQ)
Is HTA the same as marketing authorization?
No. Marketing authorisation primarily assesses quality, efficacy, and safety for market access. HTA additionally assesses the patient-relevant added benefit compared with routine care and derives reimbursement and pricing decisions from this.
Which evidence is particularly important for HTA?
Comparative data versus an appropriate comparator therapy and patient-relevant endpoints, including quality of life, are particularly important. Transparently planned analyses and a traceable approach to uncertainty are crucial.
Why can a medicinal product be authorised but receive no added benefit?
This can happen if the authorisation studies do not provide an appropriate comparator or patient-relevant endpoints, or if the evidence is insufficient for certain subgroups. In that case, HTA may arrive at a limited added-benefit conclusion despite positive efficacy data.
Regulatory References
- AMNOG (Germany): framework for early benefit assessment and subsequent price negotiations for new medicinal products.
- G-BA Rules of Procedure: methodological and procedural rules for benefit assessment in statutory health insurance.
- ICH E6(R3) Good Clinical Practice: quality requirements for study data that are also used for HTA dossiers.